Prostatic Stromal Sarcoma in a Young Adult: A Case Report

MRI Appearance of Prostatic Stromal Sarcoma in a Young Adult

“…Leiomyosarcoma is the most common histological subtype of prostate sarcoma seen in adults (6). Prostate stromal sarcoma is rarer with fewer than 30 documented cases (1)(2)(3)(4)(5)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). Most patients with prostatic sarcoma, including PSS, present with symptoms of urethral obstruction (1-3, 5, 6), as in the present case.…”

“…The mass effect of the tumor, mainly located in the central gland, probably caused the early onset of symptoms (17). In previous reports on PSS, age at diagnosis has ranged from 19 to 86 years (mean, 48 years) (1)(2)(3)(4)(5)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). PSA levels in patients with PSS including the present case have been relatively low (0.1-4.5 ng/mL) in comparison with prostatic adenocarcinoma (1,(3)(4)(5).…”

“…Primary prostate sarcomas are rare malignant tumors of the prostate gland (1,2). Leiomyosarcoma is the most common histological subtype of prostate sarcoma seen in adults (6).…”

“…Prostatic stromal sarcoma (PSS) is quite rare, comprising only 0.1-0.2% of all malignant prostate tumors (1). In 1998, Gaudin et al (2) classified sarcoma-related proliferative lesions of the specialized prostatic stroma, including prostatic phyllodes tumors, into two subtypes: prostatic stromal proliferation of uncertain malignant potential and PSS (2,3).…”

Treatment of prostatic stromal sarcoma with robot-assisted laparoscopic radical prostatectomy in a young adult: A case report

“…Reese et al (3) applied an aggressive multimodality approach in the management of a PSS, including neoadjuvant chemotherapy and radiation, which resulted in a complete response in the primary lesion, followed by radical cystoprostatectomy. Chang et al (8) reported one case of PSS treated with radical cystoprostatectomy followed by radiotherapy, and the patient was alive and well 5 months after treatment. The outcomes of these studies are challenging to interpret due to the heterogeneity of treatment modalities.…”